Remember when Moderna Inc. (MRNA) was the darling of the biotech world? The Massachusetts-based company that became a household name during the COVID-19 pandemic has had a rough few years, watching its stock crater nearly 92% from its 2021 all-time high. But something interesting is happening now. The stock is showing signs of life again, and investors are paying attention.

A Sharp Turnaround in Momentum

Here's where things get interesting. Moderna's momentum score, which tracks price movements and volatility across multiple timeframes, rocketed from 22.5 to 74.61 in just one week. That's not a typo. This kind of shift reflects a genuine change in how investors view the stock.

The numbers back it up. Shares have surged 76% from their November 2025 lows. The rally hasn't lost steam either, with the stock climbing 31.7% over the past month and tacking on another 14.8% in the past week alone. For a company that spent years in the penalty box, this is quite the comeback attempt.

Better Guidance Fuels the Rally

What's driving the turnaround? Moderna delivered better-than-expected guidance for full-year 2025. The company now projects revenue of $1.9 billion, roughly $100 million above the midpoint it provided during its third-quarter earnings call. That's a meaningful beat for a company trying to prove it has life beyond its COVID franchise.

The financial picture improved on multiple fronts. Moderna lowered its GAAP operating expense forecast by approximately $200 million for the year, showing some discipline on the cost side. Perhaps most importantly, the company increased its projected year-end cash balance to $8.1 billion. That's real money, and it gives Moderna runway to invest in its pipeline without immediately panicking about liquidity.

All of these tailwinds have aligned to create significant optimism around what had been a severely beaten-down stock. On Thursday, shares closed at $39.36, down 3.01%, but ticked up 0.66% in overnight trading. The stock now scores high on momentum metrics, showing favorable price trends across short, medium, and long-term horizons.

Whether this rally has legs or fizzles out remains to be seen, but for now, Moderna is reminding investors why momentum matters in biotech.